Citation only
via OpenAlex
Transcriptomic signature of temozolomide treatment-effect heterogeneity in IDH-wildtype glioblastoma.
Amirhossein Zare, Seyed Reza Salarikia, Amirhesam Zare, Mohammad Kashkooli, Reza Ghalehtaki, Bita Behrouzi
Journal of Clinical Oncology · 2026
Abstract
2084 Background: Adjuvant temozolomide (TMZ) is standard of care for IDH-wildtype glioblastoma (GBM), yet clinical benefit is heterogeneous and not fully explained by MGMT promoter methylation. We developed a transcriptomic signature specifically predicting TMZ benefit rather than overall prognosis using a causal inference framework. Methods: Transcriptomic and clinical data from 448 patients with histologic grade 4 IDH-wildtype GBM treated with radiotherapy alone or radiotherapy plus TMZ across six cohorts were analyzed. A training set (N=322; TCGA, CGGA-325/693, GLASS) and an independent validation set (N=126; GSE7696, CGGA-301) were used. Data were normalized, batch-corrected, and screened for outliers. To address non-random treatment assignment, inverse probability of treatment weighting (IPTW) based on propensity scores from age, sex, and MGMT status was applied. A 15-gene Temozolomide Sensitivity Score (TSS) was derived using univariate prognostic filtering followed by LASSO modeling of gene-by-treatment interactions. Final gene weights were obtained from a doubly adjusted multivariable Cox model incorporating IPTW and clinical covariates. Performance was assessed by comparing adjusted hazard ratios (HRs) for TMZ benefit across TSS-defined subgroups. Results: Five genes emerged as significant independent modulators of TMZ response: C2CD4A, SLC35E3, and DNASE1L3 predicted sensitivity, whereas APOBEC3B and PMAIP1 predicted resistance. In the training cohort, TSS-sensitive patients derived significant benefit from TMZ (median overall survival, 21.0 vs 7.7 months; adjusted HR, 0.20; 95% CI, 0.10–0.39; P<0.001), whereas TSS-resistant patients did not (14.4 vs 13.1 months; adjusted HR, 0.89; 95% CI, 0.53–1.51; P=0.674), with a significant difference in treatment effect (P<0.001). Validation confirmed these findings: TSS-sensitive patients benefited (21.9 vs 12.8 months; adjusted HR, 0.32; 95% CI, 0.16–0.62; P<0.001), while TSS-resistant patients did not (13.7 vs 15.1 months; adjusted HR, 1.25; 95% CI, 0.70–2.23; P=0.453), showing differential efficacy (P=0.003). Age, sex, and MGMT status were balanced between groups. Conclusions: A 15-gene transcriptomic signature developed through causal inference and interaction modeling is associated with differential temozolomide benefit in IDH-wildtype glioblastoma independent of MGMT status. This signature may identify patients less likely to benefit from temozolomide, offering a promising tool for de-escalation strategies and enrollment in precision clinical trials.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1200/jco.2026.44.16_suppl.2084
- Canonical
- link ↗
- Fetched
- 2026-10-15 MST
Cite this
APA
Zare, A., Salarikia, S.R., Zare, A., Kashkooli, M., Ghalehtaki, R., & Behrouzi, B. (2026). Transcriptomic signature of temozolomide treatment-effect heterogeneity in IDH-wildtype glioblastoma. <em>Journal of Clinical Oncology</em>. https://doi.org/10.1200/jco.2026.44.16_suppl.2084
Vancouver
Zare A, Salarikia SR, Zare A, Kashkooli M, Ghalehtaki R, Behrouzi B. Transcriptomic signature of temozolomide treatment-effect heterogeneity in IDH-wildtype glioblastoma. Journal of Clinical Oncology. 2026. doi:10.1200/jco.2026.44.16_suppl.2084.
BibTeX
@article{amirhossein2026Transc,
title = {Transcriptomic signature of temozolomide treatment-effect heterogeneity in IDH-wildtype glioblastoma.},
author = {Amirhossein Zare and Seyed Reza Salarikia and Amirhesam Zare and Mohammad Kashkooli and Reza Ghalehtaki and Bita Behrouzi},
journal = {Journal of Clinical Oncology},
year = {2026},
doi = {10.1200/jco.2026.44.16_suppl.2084},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Clinical and experimental immunology 2026
Citation only
Transcriptomic age acceleration is associated with plasmablast-related immune remodeling in IgG4-related disease.
Biomedicines 2025
Open access · CC-BY
sTREM-1, HMGB1, CRP, PCT, sCD14-ST, IL-6, IL-10, sHLA-G, and Vitamin D in Relation to Clinical Scores and Survival in SIRS/Sepsis
JAMA Network Open 2019
Open access · CC-BY
Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non–Small Cell Lung Cancer
Journal of Biomedical Science 2023
Open access · CC-BY
A transcriptomic pan-cancer signature for survival prognostication and prediction of immunotherapy response based on endothelial senescence
Neuro-Oncology 2014
Preprint · OA
P04.24 * MUTATIONS OF THE TERT PROMOTER CORRELATE WITH ENHANCED TELOMERASE ACTIVATION AND PREDICT A WORSE PROGNOSIS IN PRIMARY GLIOBLASTOMA PATIENTS
Scientific Reports 2024
Open access · CC-BY